<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521286</url>
  </required_header>
  <id_info>
    <org_study_id>114617</org_study_id>
    <nct_id>NCT01521286</nct_id>
  </id_info>
  <brief_title>Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain</brief_title>
  <official_title>Population Based Surveillance to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data on the incidence, complications and impact on
      quality of life of herpes zoster (HZ) disease in adults &gt;=50 years of age in Spain. This
      study will also collect data on costs related to the HZ disease, especially postherpetic
      neuralgia (PHN)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of HZ cases as recorded per participating practice, overall and within a specific age group and gender.</measure>
    <time_frame>up to one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of PHN, i.e. persistence of HZ-related pain.</measure>
    <time_frame>90, 180, and 270 days after onset of HZ.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anamnestic information, clinical parameters and complications related to HZ.</measure>
    <time_frame>Between Day 0 and Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical, direct non-medical and indirect costs related to HZ.</measure>
    <time_frame>Between Day 0 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment in HZ subjects.</measure>
    <time_frame>At Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment in HZ subjects</measure>
    <time_frame>Day 15, Day 30, Day 60 and Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical, direct non-medical and indirect costs related to PHN.</measure>
    <time_frame>At Day 90, Day 180 and Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment in PHN subjects.</measure>
    <time_frame>At Day 90, Day 180 and Day 270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment in PHN subjects.</measure>
    <time_frame>At Day 90, Day 180 and Day 270</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">552</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Subjects presenting with HZ episode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult population, male or female, ≥50 years of age presenting with a HZ episode.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female &gt;=50 years of age at the time of study enrolment presenting with
             acute HZ;

          -  HZ diagnosis for this HZ episode;

               -  is the subject's first outpatient diagnosis; OR

               -  took place at another site/ centre up to seven days before the initial visit for
                  the present study;

          -  Ability to comply with study procedures*;

          -  Written informed consent obtained from the subject*. Note: * will be applicable to
             secondary objectives only and not for the primary objective to calculate incidence.

        Exclusion Criteria:

        • Subject participating in another research study. Note: This exclusion criteria is
        applicable to secondary objectives only and not for the primary objectives to calculate
        incidence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spain</keyword>
  <keyword>cost</keyword>
  <keyword>complications</keyword>
  <keyword>incidence</keyword>
  <keyword>adults</keyword>
  <keyword>quality of life</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

